Johnson & Johnson (JNJ) PT Raised to $193 at Credit Suisse

January 27, 2021 7:51 AM EST
Get Alerts JNJ Hot Sheet
Price: $162.24 +1.15%

Rating Summary:
    17 Buy, 10 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Credit Suisse analyst Matt Miksic raised the price target on Johnson & Johnson (NYSE: JNJ) to $193.00 (from $168.00) while maintaining a Outperform rating following the company's 4Q earnings report. JNJ’s Med Devices results were in line with expectations of a late-Q4 slowdown in elective procedures, consistent with recent sector pre-announcements and commentary.

Mgmt’s 2021 organic sales growth and EPS guidance call for 8.0 - 9.5% growth (slightly above consensus) and $9.40 - 9.60, respectively (45-65c above prior estimates). Credit Suisse raised 2021 sales estimates by $1.96 bil (~2%) and increased 2021 EPS estimate by 55c (~2%), to $9.50, in line with management’s guidance.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Credit Suisse, Earnings